论文部分内容阅读
为检测人脑胶质瘤浸润淋巴细胞（TIL）的来源及其体外抗肿瘤活性，本实验应用免疫组化方法分别测定10例人脑胶质瘤TIL提取前、提取后及体外经白细胞介素－2（IL－2）刺激增殖后不同时间的细胞成分及其亚型构成。发现TIL主要为T淋巴细胞，其中CD_8阳性细胞占84．29±2．15％，CD_4阳性细胞占8．33±3．43％，B淋巴细胞浸润极少、TIL体外扩增4周．平均增加69±28．17倍，最高达120倍。体外杀伤试验表明，TIL对自体胶质瘤细胞具有高度杀伤力；对异体胶质瘤及K_562细胞也有一定杀伤作用。新鲜分离的TIL无杀瘤活性。经IL－2刺激增殖3周的TIL，杀瘤活性最强。作者认为，从手术切除的脑胶质瘤中提取、扩增的TIL，术后回输入手术瘤床，以杀灭残留的肿瘤细胞，可能成为一种较为理想的过继性免疫治疗方法.
In order to detect the source of human brain glioma infiltrating lymphocytes (TIL) and its anti-tumor activity in vitro, 10 cases of human glioma TIL were extracted before, after extraction and in vitro by means of immunohistochemistry. -2 (IL-2) stimulates proliferation of different cellular components and their subtypes. The TILs were mainly T lymphocytes, of which CD_8 positive cells accounted for 84.29±2.15%, CD_4 positive cells accounted for 8.33±3.43%, B lymphocyte infiltration was minimal, and TIL was expanded in vitro for 4 weeks. The average increase of 69 ± 28.17 times, up to 120 times. In vitro killing test showed that TIL has a high degree of lethality against autologous glioma cells, and also has a certain killing effect on allogenic gliomas and K_562 cells. Freshly isolated TIL has no tumoricidal activity. TIL stimulated by IL-2 for 3 weeks had the strongest antitumor activity. The authors believe that the extraction and amplification of TIL from surgically resected gliomas can be used as an ideal adoptive immunotherapy after entering the surgical bed after surgery to kill residual tumor cells.